Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Trastuzumab is named as an intervention in 83 current clinical trials in our China, USA, UK, India and Ireland registers. 41 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Seagen, a wholly owned subsidiary of Pfizer (4). The most-studied condition is Breast Cancer.

Trastuzumab also has an approved-drug profile on this site (FDA label data): Herceptin (Trastuzumab) →

Trials by status

Recruiting4149%
Not yet open1214%
Active, closed2935%
By invitation11%

Trials by phase

Phase 23441%
Phase 32631%
Phase 1/2810%
Phase 1810%
Phase 2/356%
Phase 422%

Clinical trials of Trastuzumab

83 trials

Study	Phase	Status	Lead sponsor	Registers
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). NCT06217185 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Advanced Breast Cancer	Phase 4	Recruiting	Hebei Medical University Fourth Hospital	China
Pre Operative Trastuzumab in Operable Breast Cancer NCT01785420 · Carcinoma Breast Stage I, HER2 Positive Breast Cancer	Phase 3	Recruiting	Dr Rajendra A. Badwe	India
A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer NCT04547907 · ClinicalTrials.gov ↗ · Breast Cancer,HER2-positive	Phase 3	Recruiting	Henan Cancer Hospital	China
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer NCT05253651 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer NCT06435429 · ClinicalTrials.gov ↗ · Metastatic HER2-positive Breast Cancer	Phase 3	Recruiting	Jazz Pharmaceuticals	UK, USA
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer NCT06532006 · ClinicalTrials.gov ↗ · Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer	Phase 3	Recruiting	Shanghai Henlius Biotech	USA, China
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT06731478 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, China
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer NCT07003074 · Breast Cancer	Phase 3	Recruiting	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	China
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer NCT07057427 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Henan Cancer Hospital	China
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients NCT07062263 · Biliary Tract Cancer, HER2-positive Cancer, Advanced Cancer	Phase 3	Recruiting	Tata Memorial Centre	India
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07315750 · ClinicalTrials.gov ↗ · Gastric Carcinoma	Phase 3	Recruiting	RemeGen Co., Ltd.	China
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer NCT07377643 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 3	Recruiting	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	China
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer NCT07441460 · ClinicalTrials.gov ↗ · Resectable HER2-positive Breast Cancer	Phase 3	Recruiting	Shanghai JMT-Bio Inc.	China
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer NCT07518173 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC NCT07797218 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3)	Phase 3	Recruiting	Shanghai Jiao Tong University School of Medicine	China
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer NCT06504732 · ClinicalTrials.gov ↗ · Stomach Neoplasms, Solid Tumor	Phase 2/3	Recruiting	SUNHO（China）BioPharmaceutical CO., Ltd.	China
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2/3	Recruiting	Hoffmann-La Roche	UK, USA, China
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer NCT05292742 · ClinicalTrials.gov ↗ · Breast Cancer, Adjuvant Therapy	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer NCT05638594 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC NCT05918328 · ClinicalTrials.gov ↗ · Breast Cancer, HER2-positive Breast Cancer	Phase 2	Recruiting	Henan Cancer Hospital	China
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing NCT06145308 · ClinicalTrials.gov ↗ · Salivary Gland Carcinoma, Precision Therapy	Phase 2	Recruiting	Peking Union Medical College	China
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer NCT06468280 · ClinicalTrials.gov ↗ · Gastric Cancer, GastroEsophageal Cancer	Phase 2	Recruiting	Shanghai Zhongshan Hospital	China
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer NCT06589830 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic, Advanced Colorectal Cancer	Phase 2	Recruiting	Suzhou Teligene Ltd.	China
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer NCT06649331 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)	Phase 2	Recruiting	Fudan University	China
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer NCT07007559 · ClinicalTrials.gov ↗ · Breast Cancer, Metastatic	Phase 2	Recruiting	ALX Oncology Inc.	UK, USA
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer NCT07102381 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Breast Cancer	Phase 2	Recruiting	Jazz Pharmaceuticals	USA
ctDNA in HER2+ EBC Neoadjuvant Treatment NCT07335081 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer NCT07340398 · ClinicalTrials.gov ↗ · HER2-positive Early Breast Cancer	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer NCT07393425 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy NCT07506057 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Biliary Tract Cancer, HER2	Phase 2	Recruiting	Xiujuan Qu	China
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer NCT07616427 · ClinicalTrials.gov ↗ · HR+/HER2+ Early Breast Cancer	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer NCT07647263 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
A Study of DB-1310 in Advanced/Metastatic Solid Tumors NCT05785741 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	DualityBio Inc.	USA, China
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread NCT06324357 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 1/2	Recruiting	Boehringer Ingelheim	UK, USA, China
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients NCT06650332 · ClinicalTrials.gov ↗ · Metastatic HER2 Positive Gastroesophageal Junction Cancer	Phase 1/2	Recruiting	Zhejiang Cancer Hospital	China
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) NCT06686394 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor NCT07140393 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors NCT07216105 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer	Phase 1	Recruiting	Fate Therapeutics	USA
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer NCT07093931 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 4	Not yet open	Shandong Cancer Hospital and Institute	China
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy NCT04973319 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Not yet open	Shengjing Hospital	China
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer NCT07779538 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer NCT05983094 · ClinicalTrials.gov ↗ · Breast Cancer, Neoadjuvant Therapy	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA) NCT06510465 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	RenJi Hospital	China
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer NCT07059338 · ClinicalTrials.gov ↗ · HER2 Positive, Colorectal Cancer (CRC)	Phase 2	Not yet open	Sun Yat-sen University	China
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. NCT07136974 · ClinicalTrials.gov ↗ · Breast Cancer, HER2 + Breast Cancer	Phase 2	Not yet open	Henan Cancer Hospital	China
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study NCT07179939 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Not yet open	Fudan University	China
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer NCT07246317 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. NCT07528898 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	Hebei Medical University Fourth Hospital	China
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer NCT07766772 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer, Advanced Breast Cancer	Phase 2	Not yet open	Fujian Cancer Hospital	China
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer NCT07795424 · ClinicalTrials.gov ↗ · Breast Cancer, HR Positive, HER2 Positive Breast Cancer	Phase 2	Not yet open	Shengjing Hospital	China
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study NCT06843681 · ClinicalTrials.gov ↗ · Breast Carcinoma in Situ	Phase 2	By invitation	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer NCT04193059 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Fudan University	China
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation NCT04208178 · ClinicalTrials.gov ↗ · Advanced HER2+Breast Cancer	Phase 3	Active, closed	Novartis Pharmaceuticals	USA, China
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) NCT04784715 · Breast Cancer; HER2-positive; Metastatic	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy NCT04873362 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, India, China
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer NCT05113251 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer NCT05132582 · ClinicalTrials.gov ↗ · HER2 Positive Breast Cancer	Phase 3	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers NCT05152147 · ClinicalTrials.gov ↗ · Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma	Phase 3	Active, closed	Jazz Pharmaceuticals	Ireland, UK, India, China
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer NCT06747338 · ClinicalTrials.gov ↗ · Early or Locally Advanced HER2-positive Breast Cancer	Phase 3	Active, closed	Shanghai JMT-Bio Inc.	China
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer NCT07196774 · ClinicalTrials.gov ↗ · Early-stage or Locally Advanced HER2-positive Breast Cancer	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) NCT05002127 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma	Phase 2/3	Active, closed	ALX Oncology Inc.	UK, USA, China
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients NCT05426486 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2/3	Active, closed	Caigang Liu	China
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer NCT05980481 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2/3	Active, closed	RemeGen Co., Ltd.	China
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies NCT00781612 · ClinicalTrials.gov ↗ · Neoplasm Metastasis	Phase 2	Active, closed	Genentech, Inc.	UK, USA, China
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC NCT04172259 · Breast Cancer, Neoadjuvant Chemotherapy	Phase 2	Active, closed	Sun Yat-sen University	China
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer NCT04398914 · ClinicalTrials.gov ↗ · Breast Cancer Invasive	Phase 2	Active, closed	Shanghai Jiao Tong University School of Medicine	China
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers NCT04430738 · Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations NCT04579380 · ClinicalTrials.gov ↗ · Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC NCT05458674 · ClinicalTrials.gov ↗ · Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer	Phase 2	Active, closed	Criterium, Inc.	USA
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma NCT05715931 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer	Phase 2	Active, closed	Yu jiren	China
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer NCT03379428 · Breast Neoplasms, Malignant Neoplasm of Breast	Phase 1/2	Active, closed	US Oncology Research	USA
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies NCT05081609 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor	Phase 1/2	Active, closed	Ascendis Pharma Oncology Division A/S	USA
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread NCT02057133 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 1	Active, closed	Eli Lilly and Company	USA
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer NCT03006172 · ClinicalTrials.gov ↗ · Breast Cancer, Solid Tumor	Phase 1	Active, closed	Genentech, Inc.	UK, USA
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers NCT03448042 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1	Active, closed	Genentech, Inc.	UK, USA, China
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer NCT04188548 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA, China
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer NCT06239467 · Advanced Cancer, Breast Cancer, Advanced Solid Tumors	Phase 1	Active, closed	OnKure, Inc.	USA
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer NCT06328738 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors	Phase 1	Active, closed	Enliven Therapeutics	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Trastuzumab

85 conditions

Breast Cancer25HER2-positive Breast Cancer10Gastric Cancer6HER2-positive Gastric Cancer5Advanced Breast Cancer5Metastatic Breast Cancer4Breast Neoplasms4Esophageal Adenocarcinoma3Gastroesophageal Junction Adenocarcinoma3Solid Tumor3HER2 + Breast Cancer3Gastric Adenocarcinoma2

All 85 conditions

Condition (as registered)	Trials
Breast Cancer	25
HER2-positive Breast Cancer	10
Gastric Cancer	6
HER2-positive Gastric Cancer	5
Advanced Breast Cancer	5
Metastatic Breast Cancer	4
Breast Neoplasms	4
Esophageal Adenocarcinoma	3
Gastroesophageal Junction Adenocarcinoma	3
Solid Tumor	3
HER2 + Breast Cancer	3
Gastric Adenocarcinoma	2
HER2 Positive Breast Cancer	2
Advanced Cancer	2
HER2-positive Early Breast Cancer	2
Ovarian Cancer	2
Advanced Solid Tumor	2
Biliary Tract Cancer	2
Gastric Neoplasms	1
Gastroesophageal Adenocarcinoma	1
Colorectal Neoplasms	1
Breast Cancer, Metastatic	1
Gastroesophageal Junction Cancer	1
Metastatic Gastric Adenocarcinoma	1
Uterine Neoplasms	1
Uterine Cervical Neoplasms	1
Biliary Tract Neoplasms	1
Urologic Neoplasms	1
Breast Cancer; HER2-positive; Metastatic	1
Neoplasm Metastasis	1
Solid Tumors	1
Metastatic HER2-positive Breast Cancer	1
Colorectal Carcinoma	1
GEJ Adenocarcinoma	1
Advanced Solid Tumors	1
PI3K Gene Mutation	1
Endometrial Cancer	1
Malignant Neoplasm of Breast	1
Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer	1
Solid Tumor, Adult	1
HER2 Mutation-Related Tumors	1
HER2 Positive Solid Tumors	1
HER2 Amplification	1
Non-Small Cell Lung Cancer	1
Colorectal Cancer	1
Locally Advanced Solid Tumor	1
Metastatic Solid Tumor	1
Platinum-resistant Ovarian Cancer	1
Advanced HER2+Breast Cancer	1
Gastroesophageal-junction Cancer	1
Monoclonal Antibody	1
Carcinoma Breast Stage I	1
HER2-positive Cancer	1
Unresectable Biliary Tract Carcinoma	1
Neoadjuvant Chemotherapy	1
Breast Cancer Early Stage Breast Cancer (Stage 1-3)	1
Stomach Neoplasms	1
Breast Carcinoma in Situ	1
HR Positive, HER2 Positive Breast Cancer	1
GastroEsophageal Cancer	1
Salivary Gland Carcinoma	1
Precision Therapy	1
Resectable HER2-positive Breast Cancer	1
Metastatic HER2 Positive Gastroesophageal Junction Cancer	1
Colorectal Cancer Metastatic	1
Advanced Colorectal Cancer	1
HER2 Positive	1
Colorectal Cancer (CRC)	1
Early or Locally Advanced HER2-positive Breast Cancer	1
Adjuvant Therapy	1
Neoadjuvant Therapy	1
Gastric Carcinoma	1
Early-stage or Locally Advanced HER2-positive Breast Cancer	1
Urothelial Carcinoma	1
HER2	1
Triple Negative Breast Cancer (TNBC)	1
HER2-negative Breast Cancer	1
Breast Cancer,HER2-positive	1
HR+/HER2+ Early Breast Cancer	1
Solid Cancer	1
Breast Cancer Invasive	1
Metastatic Gastric Cancer	1
Unresectable Gastric Carcinoma	1
Adenocarcinoma of the Stomach	1
Adenocarcinoma of Esophagogastric Junction	1

By country register

Register	Trials	Recruiting
Clinical trials in China	66	33
Clinical trials in USA	32	13
Clinical trials in UK	18	8
Clinical trials in India	7	3
Clinical trials in Ireland	2	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Trastuzumab trials

How many clinical trials are testing Trastuzumab?

83 current trials in our China, USA, UK, India and Ireland registers name Trastuzumab (also registered as TQB211) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Trastuzumab trials recruiting patients?

Yes. 41 of the 83 trials are recruiting: 33 with sites in China, 13 with sites in USA, 8 with sites in UK, 3 with sites in India and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Trastuzumab clinical trials?

Seagen, a wholly owned subsidiary of Pfizer (4), AstraZeneca (4), Shanghai Jiao Tong University School of Medicine (4) and Henan Cancer Hospital (4), among 54 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Trastuzumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trastuzumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trastuzumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Trastuzumab clinical trials